Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALNANASDAQ:MBOTNASDAQ:OCGNNASDAQ:ONVO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsMBOTMicrobot Medical$0.88+2.3%$1.16$0.86▼$4.37$12.67M1.64121,583 shs31,606 shsOCGNOcugen$1.28+8.5%$1.28$0.35▼$2.11$329.38M3.518.05 million shs5.38 million shsONVOOrganovo$1.00+1.0%$1.04$0.89▼$2.05$10.04M0.91812,263 shs139,331 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MBOTMicrobot Medical-3.12%-3.01%-23.27%-32.03%-43.40%OCGNOcugen0.00%-10.61%-31.79%+118.07%+63.89%ONVOOrganovo-1.19%-14.08%-5.90%-4.07%-44.18%The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMBOTMicrobot Medical2.0758 of 5 stars3.53.00.00.03.70.80.0OCGNOcugen0.8479 of 5 stars3.51.00.00.02.30.00.0ONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAAllena PharmaceuticalsN/AN/AN/AN/AMBOTMicrobot Medical3.00Buy$7.00695.45% UpsideOCGNOcugen3.00Buy$4.67264.58% UpsideONVOOrganovoN/AN/AN/AN/ACurrent Analyst RatingsLatest MBOT, ALNA, OCGN, and ONVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.004/16/2024MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/3/2024OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.002/22/2024OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/AMBOTMicrobot MedicalN/AN/AN/AN/A$0.38 per shareN/AOCGNOcugen$6.04M54.53N/AN/A$0.16 per share8.00ONVOOrganovo$370K27.14N/AN/A$1.76 per share0.57Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/AMBOTMicrobot Medical-$10.74M-$1.08N/A∞N/AN/A-164.13%-125.22%5/15/2024 (Estimated)OCGNOcugen-$63.08M-$0.27N/AN/AN/AN/A-102.97%-77.75%5/3/2024 (Estimated)ONVOOrganovo-$17.26M-$2.17N/AN/AN/AN/A-182.88%-138.52%7/11/2024 (Estimated)Latest MBOT, ALNA, OCGN, and ONVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/16/2024Q4 2023OCGNOcugenN/A-$0.04-$0.04-$0.04N/A$6.04 million3/27/2024Q4 2023MBOTMicrobot Medical-$0.25-$0.26-$0.01-$0.26N/AN/A2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAAllena PharmaceuticalsN/A1.581.58MBOTMicrobot MedicalN/A2.092.09OCGNOcugen0.072.512.51ONVOOrganovoN/A3.673.67OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAAllena Pharmaceuticals7.33%MBOTMicrobot Medical16.30%OCGNOcugen10.27%ONVOOrganovo8.23%Insider OwnershipCompanyInsider OwnershipALNAAllena Pharmaceuticals3.70%MBOTMicrobot Medical10.64%OCGNOcugen3.48%ONVOOrganovo4.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableMBOTMicrobot Medical2114.40 million12.87 millionOptionableOCGNOcugen84257.33 million248.37 millionOptionableONVOOrganovo1810.04 million9.64 millionOptionableMBOT, ALNA, OCGN, and ONVO HeadlinesSourceHeadlineOrganovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.comamericanbankingnews.com - April 26 at 2:18 AMOrganovo gets grant for bioprinted renal tissue for assessing renal toxicity of therapeutic agentspharmaceutical-technology.com - April 24 at 10:28 AMOrganovo's drug significantly reduces liver fat in NASH studyhealth.economictimes.indiatimes.com - April 16 at 9:35 AMWhy Organovo Stock Is Up Todaymsn.com - April 15 at 2:40 PMOrganovo’s fatty liver disease drug meets main goal in mid-stage studykfgo.com - April 15 at 9:40 AMOrganovo's fatty liver disease drug meets main goal in mid-stage studyreuters.com - April 15 at 8:28 AMOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placeboglobenewswire.com - April 15 at 8:05 AMOrganovo files patent for farnesoid x receptor agonist compound for treating diseasespharmaceutical-technology.com - March 24 at 6:42 PMOrganovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning Callsbenzinga.com - February 24 at 7:35 AMOrganovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - February 10 at 2:25 PMOrganovo Holdings Inc ONVOmorningstar.com - February 9 at 7:39 PMONVO Continues Progressfinance.yahoo.com - February 9 at 2:38 PMOrganovo: Fiscal Q3 Earnings Snapshotsfgate.com - February 8 at 7:40 PMOrganovo Holdings Unveils Corporate Presentation Onlinemsn.com - February 8 at 9:38 AMOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congressfinance.yahoo.com - January 25 at 12:43 PMOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congressfinance.yahoo.com - January 9 at 9:33 AMONVO Shares Experience Surge in Valueknoxdaily.com - January 4 at 10:15 AMChecking in on Organovo Holdings Inc (ONVO) after recent insiders movementknoxdaily.com - January 1 at 6:27 PMOrganovo Holdings: Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibitscbonds.com - December 30 at 8:48 AMOrganovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH Resultsfinanznachrichten.de - December 7 at 8:37 AMOrganovo Provides Timing for Release of FXR314 Phase 2 NASH Resultsfinance.yahoo.com - December 6 at 9:16 AMOVNO Continues Developing Breakthrough Treatmentsmsn.com - November 13 at 4:20 PMCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Planfinance.yahoo.com - November 13 at 8:43 AMOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)finance.yahoo.com - November 11 at 9:02 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AIAll Headlines Company DescriptionsAllena PharmaceuticalsNASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Microbot MedicalNASDAQ:MBOTMicrobot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.OcugenNASDAQ:OCGNOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.